BiographyDr. Greka received her MD and PhD from Harvard Medical School in the Harvard-MIT Health Sciences and Technology Program (HST). She completed her Internal Medicine residency and Nephrology Fellowship at the MGH. Dr. Greka serves as an attending physician on the inpatient nephrology consult/ICU and dialysis services, and maintains an outpatient clinical practice in Renal Associates, with a focus on proteinuric disease such as nephrotic syndrome, diabetic nephropathy and hypertensive nephropathy.

ResearchDr. Greka's research interests are the molecular mechanisms underlying proteinuria, and the development of new therapies to treat proteinuric kidney disease. Dr. Greka's laboratory is located in the MGH Research Facility at the Charlestown Navy Yard.

For the past three years newlyweds, Peter Mundel, MD, and Anna Greka, MD, PhD, both of the Division of Nephrology in the MGH Department of Medicine, have been working with other MGH colleagues on what may be the first targeted treatment for kidney diseases.

A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure.

A group of MGH investigators has identified a molecule that plays a key role in the breakdown of the kidney filter, presenting a potential therapeutic target for stopping the type of kidney damage associated with diabetes before it becomes irreversible.